Results 181 to 190 of about 432,485 (265)
SQUAMOUS CELL CARCINOMA OF THE RECTUM
Joseph P. O’Brien, Donald J. Meehan
openalex +2 more sources
High QSOX2 enhances stemness, drug resistance, and metastasis of ESCC cells. QSOX2‐mediated disulfide bond modification activates mTOR/c‐Myc signaling. CAFs‐secreted IGF‐1 drives mTOR/c‐Myc/QSOX2 positive feedback loop. Combining Ebselen, rapamycin, and cisplatin induces tumor dormancy in mice.
Wo‐Ming Chen+12 more
wiley +1 more source
A Study of Aetiological Factors in Oral Squamous Cell Carcinoma
V. Shanta, Smitha Krishnamurthi
openalex +2 more sources
Squamous Cell Carcinoma in a Gudgeon (Gobio gobio, L.) [PDF]
Lionel E. Mawdesley-Thomas, D. Bucke
openalex +1 more source
MAGEA6 Engages a YY1‐Dependent Transcription to Dictate Perineural Invasion in Colorectal Cancer
This study investigates the role of MAGEA6 in perineural invasion (PNI) in colorectal cancer (CRC). MAGEA6 promotes CRC invasiveness by inhibiting YY1 ubiquitination, enhancing CXCL1 secretion, and recruiting Schwann cells. These findings highlight the potential of targeting the MAGEA6/YY1/CXCL1 axis for therapeutic strategies against PNI and tumor ...
Hao Wang+9 more
wiley +1 more source
Basal cell carcinoma and squamous cell carcinoma of the conjunctiva in a single lesion
Introduction: Basal cell carcinoma (BCC) occurrences in the conjunctiva are exceptionally rare. These lesions become exceedingly rarer next to an adjacent area of squamous cell carcinoma.
Melissa A. Trudrung+3 more
doaj
Oral squamous cell carcinoma cells exhibit upregulated expression of GSDMD upon exposure to low‐dose cisplatin chemotherapy, which subsequently interacts with MMP14 through its N‐terminal domain, activating the epithelial‒mesenchymal transition (EMT) process and promoting the lymph node metastasis of oral squamous cell carcinoma.
Zixian Huang+9 more
wiley +1 more source
This study identifies a super‐enhancer‐driven transcriptional regulatory circuit comprising BCL6, SMAD3, and NFIB that cooperate to drive cholesterol synthesis via SREBF2/HMGCR/FDFT1 activation and regulate CDK2/CCND3 for cell cycle control. Targeting this circuit with BI‐3802 or downstream inhibitors (Fatostatin/Lovastatin) overcomes abiraterone ...
Liling Jiang+18 more
wiley +1 more source